Next Article in Journal
Application of Biodegradable and Biocompatible Nanocomposites in Electronics: Current Status and Future Directions
Previous Article in Journal
Phenol Abatement by Titanium Dioxide Photocatalysts: Effect of The Graphene Oxide Loading
Open AccessArticle

Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors

1
Departamento de Ingeniería Química y Textil, Facultad de Ciencias Químicas, Universidad de Salamanca, 37008 Salamanca, Spain
2
Instituto de Biología Molecular y Celular del Cáncer (IBMCC), CSIC, CIBERONC-IBSAL, 37007 Salamanca, Spain
*
Author to whom correspondence should be addressed.
Nanomaterials 2019, 9(7), 948; https://doi.org/10.3390/nano9070948
Received: 10 June 2019 / Revised: 26 June 2019 / Accepted: 28 June 2019 / Published: 29 June 2019
Paclitaxel is one of the most widely used chemotherapeutic agents thanks to its effectiveness and broad spectrum of antitumor activity. However, it has a very poor aqueous solubility and a limited specificity. To solve these handicaps, a novel paclitaxel-trastuzumab targeted transport nanosystem has been developed and characterized in this work to specifically treat cancer cells that overexpress the human epidermal growth factor receptor-2 (HER2). Methods: Alginate and piperazine nanoparticles were synthetized and conjugated with paclitaxel:β-cyclodextrins complexes and trastuzumab. Conjugated nanoparticles (300 nm) were characterized and their internalization in HER2-overexpressing tumor cells was analyzed by immunofluorescence. Its specific antitumor activity was studied in vitro using human cell lines with different levels of HER2-expression. Results: In comparison with free paclitaxel:β-cyclodextrins complexes, the developed conjugated nanovehicle presented specificity for the treatment of HER2-overpressing cells, in which it was internalized by endocytosis. Conclusions: It seems that potentially avoiding the conventional adverse effects of paclitaxel treatment could be possible with the use of the proposed mixed nanovehicle, which improves its bioavailability and targets HER2-positive cancer cells. View Full-Text
Keywords: targeted nanoparticles; paclitaxel; trastuzumab; HER2-specificity; sodium alginate; piperazine targeted nanoparticles; paclitaxel; trastuzumab; HER2-specificity; sodium alginate; piperazine
Show Figures

Graphical abstract

MDPI and ACS Style

Nieto, C.; Centa, A.; Rodríguez-Rodríguez, J.A.; Pandiella, A.; Martín del Valle, E.M. Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors. Nanomaterials 2019, 9, 948. https://doi.org/10.3390/nano9070948

AMA Style

Nieto C, Centa A, Rodríguez-Rodríguez JA, Pandiella A, Martín del Valle EM. Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors. Nanomaterials. 2019; 9(7):948. https://doi.org/10.3390/nano9070948

Chicago/Turabian Style

Nieto, Celia; Centa, Ariana; Rodríguez-Rodríguez, Jesús A.; Pandiella, Atanasio; Martín del Valle, Eva M. 2019. "Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors" Nanomaterials 9, no. 7: 948. https://doi.org/10.3390/nano9070948

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop